Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 24, 2021
- Accepted January 10, 2022
- Published online January 14, 2022.
Article Versions
- You are currently viewing a previous version of this article (January 14, 2022 - 05:26).
- View the most recent version of this article
Copyright & Usage
Copyright © 2022, Parenteral Drug Association
Author Information
- Melisa J. Masuda-Herrera1,15 (melisa.masuda-herrera@gilead.com),
- Joel P. Bercu1 (joel.bercu@gilead.com),
- Thomas H. Broschard2 (thomas.broschard@merckgroup.com),
- Anders Burild3 (qabu@novonordisk.com),
- Catrin Hasselgren4 (hasselgren.catrin@gene.com),
- Patricia Parris5 (patricia.parris@pfizer.com),
- Lucie C. Ford6 (lucie.ford@tamu.edu),
- Jessica Graham4 (graham.jessica@gene.com),
- Brad Stanard7 (bstanard@ultragenyx.com),
- Michele Comerford8 (michele.comerford@pfizer.com),
- Daniel Lettiere8 (daniel.j.lettiere@pfizer.com),
- Steffen Erler9 (steffen.erler@wella.com),
- Courtney M. Callis10 (courtney.callis@lilly.com),
- Eric Morinello4 (morinello.eric@gene.com),
- Wolfgang Muster11 (wolfgang.muster@roche.com),
- Elizabeth A. Martin12 (elizabeth.martin@astrazeneca.com),
- Troy R. Griffin13 (troy.griffin@tevapharm.com),
- Lee Nagao14 (lee.nagao@faegredrinker.com) and
- Maureen Cruz14 (maureen.cruz@faegredrinker.com)
- 1 Gilead Sciences;
- 2 Merck KGaA;
- 3 Novo Nordisk A/S;
- 4 Genentech, Inc.;
- 5 Pfizer Worldwide Research and Development;
- 6 Texas A&M University;
- 7 Ultragenyx Pharmaceutical Inc.;
- 8 Pfizer Global Research & Development;
- 9 Wella Company;
- 10 Eli Lilly & Company;
- 11 Roche Pharmaceutical Research & Early Development;
- 12 AstraZeneca;
- 13 Teva Branded Pharmaceutical Products R&D;
- 14 Faegre Drinker Biddle & Reath LLP
- ↵* Corresponding author; email: melisa.masuda-herrera@gilead.com
